All In MedTech

Device Trial Radar · NCT03238469

Microwave Ablation in Mild Axillary Hidradenitis Suppurativa

Long-term Efficacy and Safety of Microwave Ablation in the Treatment of Mild Axillary Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Jun 25, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

9

Actual

Start

Sep 1, 2017

Primary completion

Apr 1, 2018

Study completion Apr 1, 2018

Sponsor

Lead sponsor
M.B.A. van DoornAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Erasmus Medical Center
First posted
Aug 3, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

With microwave ablation (MWA), using the heat generated from electromagnetic waves in the microwave energy spectrum, hair follicles and apocrine glands in the (hypo)dermis are ablated through thermolysis. MWA was recently approved for the treatment of axillary hyperhidrosis (miraDry) and removal of axillary hair (miraSmooth). By permanent removal of hairs and sweat glands, the investigators hypothesize a beneficial and long-term sustainable preventive effect of MWA in HS patients.

Conditions

  • Hidradenitis Suppurativa
  • Acne Inversa

Interventions

  • Microwave ablationDevice

    A one-sided (either right or left axillary area) single MWA treatment using a miraDry system. The miraDry device has a microwave output frequency of 5.8 GHz and microwave energy level settings ranging from 1 to 5, corresponding with a delivery time in seconds between 2.40 sec and 3.00 sec. For this study standard 5 (i.e. 3.00 sec) is set as treatment setting.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hidradenitis Suppurativa Clinical Response (HiSCR50)Time frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Erasmus University Medical Center

    Rotterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.